Detailed information for compound 74332
Basic information
Technical information
- Name: Unnamed compound
- MW: 314.356 | Formula: C17H14O4S
-
H donors: 0
H acceptors: 3
LogP: 2.56
Rotable bonds: 3
Rule of 5 violations (Lipinski): 1 - SMILES: O=C1COC(=C1c1ccccc1)c1ccc(cc1)S(=O)(=O)C
- InChi: 1S/C17H14O4S/c1-22(19,20)14-9-7-13(8-10-14)17-16(15(18)11-21-17)12-5-3-2-4-6-12/h2-10H,11H2,1H3
- InChiKey: KWNQZRYTBLYWKU-UHFFFAOYSA-N
Network
Hover on a compound node to display the structore
Synonyms
No synonyms found for this compound
Targets
Known targets for this compound
No curated genes were found associated with this compound
Predicted pathogen targets for this compound
By orthology
No druggable targets predicted by orthology data
By sequence similarity to non orthologous known druggable targets
No druggable targets predicted by sequence similarity
Obtained from network model
Ranking Plot
Putative Targets List
| Species | Potential target | Raw | Global | Species |
|---|---|---|---|---|
| Entamoeba histolytica | hypothetical protein | 0.0081 | 0.5 | 0.5 |
| Echinococcus multilocularis | Basic leucine zipper (bZIP) transcription | 0.0081 | 0.5 | 0.5 |
| Entamoeba histolytica | hypothetical protein | 0.0081 | 0.5 | 0.5 |
| Entamoeba histolytica | hypothetical protein | 0.0081 | 0.5 | 0.5 |
| Entamoeba histolytica | hypothetical protein | 0.0081 | 0.5 | 0.5 |
| Schistosoma mansoni | hypothetical protein | 0.0081 | 0.5 | 0.5 |
| Schistosoma mansoni | transcription factor LCR-F1 | 0.0081 | 0.5 | 0.5 |
| Echinococcus granulosus | Basic leucine zipper bZIP transcription | 0.0081 | 0.5 | 0.5 |
Activities
| Activity type | Activity value | Assay description | Source | Reference |
|---|---|---|---|---|
| Activity (functional) | 0 | Cell cycle arrest in human LNCaP cells assessed as induction of G1 block at 100 uM by FACS flow cytometry | ChEMBL. | 15566290 |
| Activity (functional) | = 0 % | Antiproliferative activity against androgen-sensitive human LNCaP cells at 100 uM after 72 hrs by MTT test | ChEMBL. | 15566290 |
| Activity (functional) | = 4 % | Cell cycle arrest in human LNCaP cells by accumulation at subG1 phase at 10 uM after 72 hrs by FACS flow cytometry | ChEMBL. | 15566290 |
| Activity (functional) | = 11.4 % | Cell cycle arrest in human LNCaP cells by accumulation at S phase at 10 uM after 72 hrs by FACS flow cytometry | ChEMBL. | 15566290 |
| Activity (functional) | = 15 % | Antiproliferative activity against androgen-independent human PC3 cells at 100 uM after 72 hrs by MTT test | ChEMBL. | 15566290 |
| Activity (functional) | = 15.2 % | Cell cycle arrest in human LNCaP cells by accumulation at G2M phase at 10 uM after 72 hrs by FACS flow cytometry | ChEMBL. | 15566290 |
| Activity (functional) | = 69.4 % | Cell cycle arrest in human LNCaP cells by accumulation at G1 phase at 10 uM after 72 hrs by FACS flow cytometry | ChEMBL. | 15566290 |
| IC50 (binding) | = 0.43 uM | In vitro inhibitory activity against prostaglandin G/H synthase 2 (COX-2) | ChEMBL. | 14584938 |
| IC50 (binding) | = 1 uM | In vitro inhibitory activity against human whole blood Prostaglandin G/H synthase 2 | ChEMBL. | 10406640 |
| IC50 (binding) | = 6.3 uM | In vitro inhibitory activity against human whole blood Prostaglandin G/H synthase 1 | ChEMBL. | 10406640 |
| IC50 (binding) | > 500 uM | In vitro inhibitory activity against Prostaglandin G/H synthase 1 (COX-1) | ChEMBL. | 14584938 |
| Ratio (binding) | = 6.3 | Ratio of IC50 values at Cyclooxygenase-1 and Cyclooxygenase-2 | ChEMBL. | 10406640 |
| Selectivity index (binding) | > 1162 | Selectivity index of IC50 against COX-1 to the IC50 against COX-2 | ChEMBL. | 14584938 |
Phenotypes
Whole-cell/tissue/organism interactions
We have no records of whole-cell/tissue assays done with this compound
What does this mean?
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
Annotated phenotypes:
We have no manually annotated phenotypes for this drug.
What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by
drugs, or by genetic manipulation of cells (e.g. gene knockouts or
knockdowns) is manually curated from the literature. These
descriptions help to describe the potential of the target for drug
development. If no information is available for this gene or if the
information is incomplete, this may mean that i) the papers
containing this information either appeared after the curation
effort for this organism was carried out or they were inadvertently
missed by curators; or that ii) the curation effort for this
organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.
External resources for this compound
- ChEMBL: 176801
Bibliographic References
3 literature references were collected for this gene.
If you have references for this compound, please enter them in a user comment (below) or Contact us.